Comprehensive evaluation of plasma tau biomarkers for detecting and monitoring Alzheimer's disease in a multicenter and multiethnic aging population.

IF 17 Q1 CELL BIOLOGY

Nature aging Pub Date : 2025-06-23 DOI:10.1038/s43587-025-00904-3

Guoyu Lan, Mengjie Wang, Fernando Gonzalez-Ortiz, Laihong Zhang, Anqi Li, Binyin Li, Mingxing Jiang, Jie Yang, Xuhui Chen, Dai Shi, Xiang Fan, Yue Cai, Pan Sun, Lin Liu, Jieyin Li, Zhengbo He, Lili Fang, Xin Zhou, Linting Chen, Yiying Wang, Mingxu Li, Zhen Liu, Qingyong Wang, Linsen Xu, Liemin Zhou, Guanxun Cheng, Xinlu Wang, Pengcheng Ran, Lu Wang, Kun Sun, Ying Han, Yihui Guan, Kaj Blennow, Fang Xie, Tengfei Guo

{"title":"Comprehensive evaluation of plasma tau biomarkers for detecting and monitoring Alzheimer's disease in a multicenter and multiethnic aging population.","authors":"Guoyu Lan, Mengjie Wang, Fernando Gonzalez-Ortiz, Laihong Zhang, Anqi Li, Binyin Li, Mingxing Jiang, Jie Yang, Xuhui Chen, Dai Shi, Xiang Fan, Yue Cai, Pan Sun, Lin Liu, Jieyin Li, Zhengbo He, Lili Fang, Xin Zhou, Linting Chen, Yiying Wang, Mingxu Li, Zhen Liu, Qingyong Wang, Linsen Xu, Liemin Zhou, Guanxun Cheng, Xinlu Wang, Pengcheng Ran, Lu Wang, Kun Sun, Ying Han, Yihui Guan, Kaj Blennow, Fang Xie, Tengfei Guo","doi":"10.1038/s43587-025-00904-3","DOIUrl":null,"url":null,"abstract":"<p><p>Over 20% of patients with Alzheimer's disease (AD) worldwide are Chinese, although the efficacy of existing blood-based measures of AD biomarkers is largely unknown in Asian cohorts. Here we explored how plasma tau biomarkers correlated with cross-sectional and longitudinal AD-related outcomes and their diagnostic performance in 1,085 participants from three independent studies, including two Chinese cohorts, Greater-Bay-Area Healthy Aging Brain Study (n = 425) and Huashan (n = 297), and the North American Alzheimer's Disease Neuroimaging Initiative cohort (n = 363). Plasma p-tau217 performed best in classifying Aβ-positron emission tomography (PET) and tau-PET positivity throughout the AD continuum and correlated with all AD-related outcomes. A two-cutoff approach suggested that participants with intermediate plasma p-tau217 levels experienced rapid accumulation of Aβ-PET and entorhinal tau-PET, as well as accelerated hypometabolism and cognitive decline. Increased plasma p-tau217 was also associated with rapid longitudinal changes in Aβ-PET, tau-PET and neurodegeneration. These results suggest that plasma p-tau217 is superior in detecting multiple aspects of AD-related pathological changes and tracking disease progression.</p>","PeriodicalId":94150,"journal":{"name":"Nature aging","volume":" ","pages":""},"PeriodicalIF":17.0000,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature aging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/s43587-025-00904-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Over 20% of patients with Alzheimer's disease (AD) worldwide are Chinese, although the efficacy of existing blood-based measures of AD biomarkers is largely unknown in Asian cohorts. Here we explored how plasma tau biomarkers correlated with cross-sectional and longitudinal AD-related outcomes and their diagnostic performance in 1,085 participants from three independent studies, including two Chinese cohorts, Greater-Bay-Area Healthy Aging Brain Study (n = 425) and Huashan (n = 297), and the North American Alzheimer's Disease Neuroimaging Initiative cohort (n = 363). Plasma p-tau217 performed best in classifying Aβ-positron emission tomography (PET) and tau-PET positivity throughout the AD continuum and correlated with all AD-related outcomes. A two-cutoff approach suggested that participants with intermediate plasma p-tau217 levels experienced rapid accumulation of Aβ-PET and entorhinal tau-PET, as well as accelerated hypometabolism and cognitive decline. Increased plasma p-tau217 was also associated with rapid longitudinal changes in Aβ-PET, tau-PET and neurodegeneration. These results suggest that plasma p-tau217 is superior in detecting multiple aspects of AD-related pathological changes and tracking disease progression.

查看原文本刊更多论文

血浆tau生物标志物在多中心、多种族老龄化人群中检测和监测阿尔茨海默病的综合评价

全球超过20%的阿尔茨海默病（AD）患者是中国人，尽管现有的基于血液的AD生物标志物测量方法在亚洲队列中的有效性在很大程度上是未知的。血浆p-tau217在整个AD连续体中对a β-正电子发射断层扫描（PET）和tau-PET阳性进行分类的效果最好，并与所有AD相关的结果相关。双截断方法表明，血浆p-tau217水平处于中间水平的参与者经历了Aβ- pet和内鼻tau-PET的快速积累，以及加速代谢低下和认知能力下降。血浆p-tau217升高还与Aβ-PET、tau-PET和神经变性的快速纵向变化有关。这些结果表明血浆p-tau217在检测ad相关的多个方面的病理改变和跟踪疾病进展方面具有优势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature aging

CiteScore

14.70

自引率

0.00%

发文量